Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05274269
Recruitment Status : Recruiting
First Posted : March 10, 2022
Last Update Posted : June 3, 2022
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated

Brief Summary:
This study will evaluate the efficacy, pharmacodynamics (PD) and safety of ELX/TEZ/IVA in participants 6 years of age and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: ELX/TEZ/IVA Drug: IVA Other: Placebo (matched to ELX/TEZ/IVA) Other: Placebo (matched to IVA) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 270 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-responsive CFTR Mutation
Actual Study Start Date : May 9, 2022
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : May 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis
Drug Information available for: Ivacaftor

Arm Intervention/treatment
Experimental: ELX/TEZ/IVA
Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
Fixed-dose combination (FDC) tablets for oral administration.
Other Names:
  • VX-445/VX-661/VX-770
  • elexacaftor/tezacaftor/ivacaftor

Drug: IVA
Tablet for oral administration.
Other Names:
  • VX-770
  • ivacaftor

Placebo Comparator: Placebo
Participants will receive placebo matched to ELX/TEZ/IVA in the morning and placebo matched to IVA in the evening.
Other: Placebo (matched to ELX/TEZ/IVA)
Placebo matched to ELX/TEZ/IVA for oral administration.

Other: Placebo (matched to IVA)
Placebo matched to IVA for oral administration.

Primary Outcome Measures :
  1. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) [ Time Frame: From Baseline Through Week 24 ]

Secondary Outcome Measures :
  1. Absolute Change in Sweat Chloride (SwCl) [ Time Frame: From Baseline Through Week 24 ]
  2. Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score [ Time Frame: From Baseline Through Week 24 ]
  3. Absolute Change in Body Mass Index (BMI) [ Time Frame: From Baseline at Week 24 ]
  4. Absolute Change in Weight [ Time Frame: From Baseline at Week 24 ]
  5. Number of Pulmonary Exacerbations (PEx) [ Time Frame: From Baseline Through Week 24 ]
  6. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Day 1 up to Week 28 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Participant has a qualifying ELX/TEZ/IVA-responsive CFTR mutation and does not have an exclusionary CFTR mutation
  • Forced expiratory volume in 1 second (FEV1) value >=40% and <=90% of predicted mean for age, sex, and height

Key Exclusion Criteria:

  • History of solid organ or hematological transplantation
  • Clinically significant cirrhosis with or without portal hypertension
  • Lung infection with organisms associated with a more rapid decline in pulmonary status

Other protocol defined Inclusion/Exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05274269

Layout table for location contacts
Contact: Medical information 617-341-6777

Layout table for location information
CHU Lyon - Hopital Femme Mere-Enfant Recruiting
Bron Cedex, France
CHU Marseille - Hopital Nord Recruiting
Marseilles, France
Hopital Arnaud de Villeneuve Recruiting
Montpellier Cedex 5, France
Centre Hospitalier Universitaire De Nantes - G. R. Laennec Recruiting
Nantes, France
Centre Hospitalier Universitaire (CHU) de Nice - Hopital Pasteur Recruiting
Nice, France
Centre de Perharidy Recruiting
Roscoff Cedex, France
Hopital Bretonneau Recruiting
Tours, France
Academisch Medisch Centrum (Academic Medical Centre) Recruiting
Amsterdam, Netherlands
Hospital Saint Joan de Deu Recruiting
Barcelona, Spain
Hospital Universitario Ramon y Cajal Recruiting
Madrid, Spain
Hospital Virgen de la Arrixaca Recruiting
Murcia, Spain
Hospital Universitario Virgen del Rocio Recruiting
Sevilla, Spain
Kinderspital Zuerich Recruiting
Zurich, Switzerland
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
Layout table for additonal information
Responsible Party: Vertex Pharmaceuticals Incorporated Identifier: NCT05274269    
Other Study ID Numbers: VX21-445-124
2021-005320-38 ( EudraCT Number )
First Posted: March 10, 2022    Key Record Dates
Last Update Posted: June 3, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Details on Vertex data sharing criteria and process for requesting access can be found at:

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Chloride Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action